THERAPEUTIC INDICATIONS: It is indicated for the treatment of urinary tract infections and concomitant symptoms caused bygram-negative organisms sensitive to nalidixic acid, includingKlebsiella, Enterobacter, E. coli and most strains of Proteus.
CONTRAINDICATIONS: Do not be administered to patients with known hypersensitivity to nalidixic acid or in patients with a history of seizures. By its content of Phenazopyridine is contraindicated in hepatic and renal failure.
Do not administer during pregnancy, breastfeeding or under 18years.
PRECAUTIONS General: Patients should be advised to avoid exposure to sunlight during treatment, in order to avoidphotosensitivity reactions, if they were to occur, discontinuetherapy.
If clinical response is unsatisfactory, or if relapse, urine andsusceptibility testing should be performed as they may arisenalidixic acid-resistant strains relatively quickly. Not given to children under one year.
DOSAGE AND ADMINISTRATION: Oral.
Adults: 2 tablets every 6 hours.
Total daily dose: 8 tablets.
It is advisable to recommend the administration on an empty stomach, preferably 1 hour before meals. Patients should be advised that produces a red coloration of the urine.